2. GPCR/G Protein
  3. GCGR
  4. Pegsebrenatide

Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension. Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis. Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Pegsebrenatide

Pegsebrenatide Chemical Structure

CAS No. : 2243292-26-2

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Pegsebrenatide Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension. Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis. Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis[1][2][3][4].

In Vitro

Pegsebrenatide (2 h) is a potent GLP1R agonist that induces cAMP production in GLP1R-transfected HEK293 cells[4].
Pegsebrenatide (1 μM) inhibits the increased expression levels of pro-inflammatory activation marker genes (Il1a, Il1b, Tnf, C1qa, Il6) and the elevated secretion of pro-inflammatory cytokines (IL-1α, TNFα, C1q) induced by α-syn PFF in mouse primary microglia, blocks α-syn PFF-induced conversion of mouse primary astrocytes to neurotoxic A1 reactive astrocytes, and thereby prevents α-syn PFF-ACM-induced death of mouse primary cortical neurons and dopaminergic neurons[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pegsebrenatide Related Antibodies
Parmacokinetics
Species Dose Route T1/2 Cmax Tmax MRT AUCinf
Monkey[4] 32 μg/kg s.c. 88 h 52.7 ng/mL 72 h 114 h 6833.5 ng·h/mL
In Vivo

Pegsebrenatide (NLY01) (5 mg/kg per injection; subcutaneous; twice weekly; 14 or 42 days) reduces retinal inflammatory cytokine production, A1 astrocyte transformation, and protects against RGC death, resulting in ~98% Brn3a+ and ~100% Rbpms+ RGC survival in a microbead-induced mouse model of glaucoma[1].
Pegsebrenatide (10 mg/kg; s.c.; twice weekly; 42 days) significantly delays EAE onset, attenuates disease severity, suppresses peripheral and CNS inflammation, and prevents RGC loss in chronic EAE[3].
Pegsebrenatide (NLY01) (3 mg/kg; s.c.; twice weekly; 5 months) exerts robust neuroprotective and behavioral rescue effects in the α-syn PFF mouse model of Parkinson's disease by inhibiting microglial activation and subsequent A1 astrocyte formation[4].
Pegsebrenatide (3 mg/kg; s.c.; twice weekly; until endpoint (10 months of age or death)) significantly extends survival and reduces neuropathological abnormalities in hA53T transgenic mice with familial α-synucleinopathy[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (adult, glaucoma induced by magnetic microbead injection into anterior chamber)[1]
Dosage: 5 mg/kg per injection
Administration: subcutaneous; twice weekly; 14 or 42 days
Result: Reduced Tnf mRNA upregulation in CD11b+ CD11c− cells at 14 days post-injection.
Reduced Il1a, Tnf, and C1qa mRNA upregulation in CD11b+ CD11c+ cells at 14 days post-injection.
Reduced expression of pan-reactive (Lcn2, Steap4, Gfap) and A1-specific (Serping1, Fkbp5, Amigo2) transcripts, and reduced C3 mRNA levels in ACSA2+ cells at 14 days post-injection.
Reduced Il1a, Tnf, and C1qa mRNA upregulation in both CD11b+ CD11c− and CD11b+ CD11c+ cells at 42 days post-injection.
Reduced expression of pan-reactive (Lcn2, Steap4, Gfap) and A1-specific (Serping1, Fkbp5, Amigo2) transcripts, and reduced C3 mRNA levels in ACSA2+ cells at 42 days post-injection.
Increased retinal ganglion cell (RGC) survival, with Brn3a+ RGC survival normalized to fellow control eyes reaching ~98% and Rbpms+ RGC survival normalized to fellow control eyes reaching ~100% at 42 days post-injection.
Animal Model: C57BL/6J (9-week-old)[3]
Dosage: 10 mg/kg
Administration: s.c.; twice weekly; 42 days
Result: Significantly delayed EAE onset and attenuated disease severity, with a statistically significant reduction in cumulative clinical scores.
Significantly reduced spleen weight, absolute counts of CD45+ splenocytes, and absolute counts/percentages of CD11b+ myeloid cells (including CD11b+Ly6G+ neutrophils, CD11b+MHCII+ activated myeloid cells, and CD11b+CD11c+ dendritic cells) at PID 6.
Significantly reduced percentages/absolute counts of CD11b+MHCII+ activated myeloid cells and CD4+CD44+ effector/memory T cells in the spleen at PID 11.
Significantly reduced percentages of CD45 high infiltrating leukocytes, Clec12a+ monocytes, and CD4+CD44+ effector/memory T cells in the brain and spinal cord at PID 11.
Significantly reduced hindbrain expression of reactive astrocyte marker Lcn2 and chemokines Ccl8 and Cxcl1 at PID 11.
Significantly reduced retinal ganglion cell (RGC) loss (with more pronounced protection in central and peripheral retinal regions) at PID 42.
Significantly downregulated optic nerve expression of neurotoxic astrocyte genes (C3, Ligp1, Psmb8, H2-T23, H2-D1) and pro-inflammatory cytokine Tnfα at PID 42.
Animal Model: C57BL/6 (mixed male and female, 3 months old, intrastriatal stereotaxic injection of α-synuclein preformed fibrils)[4]
Dosage: 3 mg/kg
Administration: s.c.; twice weekly; 5 months
Result: Significantly reduced p-α-synSer129 immunoreactivity in the striatum, ventral midbrain, and tyrosine hydroxylase (TH)-positive neurons.
Prevented α-syn PFF-induced loss of TH-positive and Nissl-positive neurons in the substantia nigra pars compacta (SNpc).
Normalized striatal dopamine levels and dopamine metabolite ratios.
Abolished α-syn PFF-induced ipsilateral amphetamine rotation.
Reduced deficits in the pole test, accelerating rotarod test, and cylinder test.
Restored grooming time and rearing behavior.
Reduced α-syn PFF-induced microglial activation (IBA1 immunoreactivity and density) in the SNpc.
Blocked α-syn PFF-induced astrocytic activation (GFAP immunoreactivity and protein levels) and formation of neurotoxic A1 astrocytes (C3d immunoreactivity and C3 mRNA expression) in the ventral midbrain.
Animal Model: hA53T α-synuclein transgenic (C57BL/6, mixed male and female, 6 months old, familial Parkinson's disease model via constitutive expression of human A53T α-synuclein)[4]
Dosage: 3 mg/kg
Administration: s.c.; twice weekly; until endpoint (10 months of age or death)
Result: Prolonged lifespan by over 100 days.
Reduced p-α-synSer129 immunoreactivity, α-synuclein aggregation, and ubiquitin immunoreactivity in the lateral vestibular nucleus (LVe) of the brainstem.
Decreased levels of Triton X-100-insoluble α-synuclein and p-α-synSer129 in the brainstem.
Attenuated microglial activation (IBA1 immunoreactivity) and astrocytic activation (GFAP immunoreactivity) in brain tissue.
Formula

C₂₀₆H₃₁₈N₅₄O₆₉S₂(C₂H₄O)m+₂n; m≈₁₀; n≈₂₀
CAS No.
Appearance

Solid

Color

White to off-white

Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

Solvent & Solubility
In Vitro: 

H2O : ≥ 100 mg/mL

DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 95.50%

SDS (252 KB)

COA (249 KB) RP-HPLC (230 KB) LCMS (125 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Pegsebrenatide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pegsebrenatide2243292-26-2NLY01NLY 01NLY-01GCGRGlucagon ReceptorGLP-1R agonistglaucomaParkinson's diseaseand multiple sclerosisHEK293 cellsmouse primary microgliaC57BL/6J mice
Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Pegsebrenatide
Cat. No.:
HY-P10019
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.